Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Myeloid Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Hematopoietic and Lymphoid Cell Neoplasm
Myeloid Neoplasm

Cancer Family

Myeloid Neoplasm

CI-CAN-00000279Explore in graph →

HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items

NCIt: C9290
OncoTree: MNM
DOID: 0070004

Overview
Statistics
Survival
Genomics22
Variants & evidence653
Drugs61
Trials4789
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (234)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 151–175 of 234 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
· Leukemia · 2010 · PMID 20376086 · validated civic_curation pubmed
Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
· J Clin Oncol · 2010 · PMID 20368538 · validated civic_curation pubmed
Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.
· Leuk Lymphoma · 2012 · PMID 22616558 · validated civic_curation pubmed
IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
· Ann Hematol · 2012 · PMID 21997850 · validated civic_curation pubmed
U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
· PLoS One · 2012 · PMID 23029227 · validated civic_curation pubmed
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
· Clin Cancer Res · 2014 · PMID 24178622 · validated civic_curation pubmed
IDH1 inhibitor shows promising early results.
· Cancer Discov · 2015 · PMID 25583779 · validated civic_curation

Showing 151–175 of 234 publications

← Previous
1
…
6
7
8
9
10
Next →

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.

· BMC Cancer · 2016 · PMID 27485109 · validated civic_curation pubmed

Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications.

· Blood · 2014 · PMID 24335498 · validated civic_curation pubmed

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

· Blood · 2007 · PMID 17264298 · validated civic_curation pubmed

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

· Blood · 2005 · PMID 15459012 · validated civic_curation pubmed

A novel inherited mutation of the transcription factor RUNX1 causes thrombocytopenia and may predispose to acute myeloid leukaemia.

· Br J Haematol · 2002 · PMID 12060124 · validated civic_curation pubmed

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.

· Blood · 2011 · PMID 21613260 · validated civic_curation pubmed

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

· Proc Natl Acad Sci U S A · 2004 · PMID 15448205 · validated civic_curation pubmed

In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.

· Blood · 2002 · PMID 11830488 · validated civic_curation pubmed

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

· Blood · 2003 · PMID 12623848 · validated civic_curation pubmed

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

· N Engl J Med · 2006 · PMID 16775234 · validated civic_curation pubmed

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

· Nature · 2015 · PMID 25686603 · validated civic_curation pubmed

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.

· Leuk Res Rep · 2014 · PMID 25180155 · validated civic_curation pubmed

Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.

· J Clin Invest · 2018 · PMID 29920189 · validated civic_curation pubmed

A new genomic framework to categorize pediatric acute myeloid leukemia.

· Nat Genet · 2024 · PMID 38212634 · validated cbioportal_study pubmed

Acute promyelocytic leukemia with PML/RARA (bcr1, bcr2 and bcr3) transcripts in a pediatric patient.

· Oncol Lett · 2024 · PMID 38304177 · validated civic_curation pubmed

Identification of atypical PML-RARA breakpoint in a patient with acute promyelocytic leukemia.

· Acta Haematol · 2007 · PMID 17934255 · validated civic_curation pubmed

Identification and monitoring of atypical PML/RARA fusion transcripts in acute promyelocytic leukemia.

· Genes Chromosomes Cancer · 2019 · PMID 30421475 · validated civic_curation pubmed

Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

· JAMA · 2011 · PMID 21505136 · validated civic_curation pubmed